{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:45:53Z","timestamp":1778539553378,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The rapid integration of immune checkpoint inhibitor (ICI) based combination therapies in first-line treatment of metastatic renal cell carcinoma (mRCC) is raising questions about next-line treatments and outcomes of ICI rechallenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a meta-analysis using the results from the phase-III RCTs, CONTACT-03 and TiNivo-2, to evaluate the effect of adding a PD-1\/PD-L1 inhibitor rechallenge to a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) vs a VEGF TKI alone in patients with mRCC who had progressed on ICI based combination therapy or ICI monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 865 patients with mRCC were included in this meta-analysis. The meta-analysis showed no difference in progression free survival between ICI plus VEFG TKI combination and TKI monotherapy groups (HR\u2009=\u20090.96, 95% CI, 0.76-1.21; P =\u2009.75) in patients previously progressing on ICI. Furthermore, adding ICI to anti-VEGF TKI therapy was not associated with improve overall survival (HR\u2009=\u20091.06, 95% CI, 0.89-1.25; P =\u2009.52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, PD-1\/PD-L1 inhibitor rechallenge with a VEGF TKI in mRCC does not improve survival outcomes and should not be used in patients with prior progression to ICI. Understanding both intrinsic and acquired resistance mechanisms to ICI therapy is crucial for developing effective initial and sequential immunotherapy strategies in RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf426","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:56:20Z","timestamp":1766494580000},"source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials"],"prefix":"10.1093","volume":"31","author":[{"given":"Hatice","family":"Bolek","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara University School of Medicine , Ankara 06620, T\u00fcrkiye"},{"name":"Ankara University Cancer Research Institute , Ankara 06620, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sat\u0131 Coskun","family":"Yazgan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University School of Medicine , Ankara 06620, T\u00fcrkiye"},{"name":"Ankara University Cancer Research Institute , Ankara 06620, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emre","family":"Yeked\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University School of Medicine , Ankara 06620, T\u00fcrkiye"},{"name":"Ankara University Cancer Research Institute , Ankara 06620, T\u00fcrkiye"},{"name":"Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA 02215,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley A","family":"McGregor","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA 02215,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana R","family":"McKay","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego , La Jolla, CA 92307,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA 91010,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni K","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA 02215,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University School of Medicine , Ankara 06620, T\u00fcrkiye"},{"name":"Ankara University Cancer Research Institute , Ankara 06620, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2026012601215807800_oyaf426-B1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"2026012601215807800_oyaf426-B2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"2026012601215807800_oyaf426-B3","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026012601215807800_oyaf426-B4","doi-asserted-by":"publisher","first-page":"996553","DOI":"10.3389\/fonc.2022.996553","article-title":"Immune-based treatment re-challenge in renal cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Papathanassiou","year":"2022","journal-title":"Front Oncol"},{"key":"2026012601215807800_oyaf426-B5","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.3390\/jcm13123365","article-title":"Efficacy and safety of immuno-oncology plus tyrosine kinase inhibitors as late-line combination therapy for patients with advanced renal cell carcinoma","volume":"13","author":"Hamamoto","year":"2024","journal-title":"J Clin Med"},{"key":"2026012601215807800_oyaf426-B6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026012601215807800_oyaf426-B7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026012601215807800_oyaf426-B8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026012601215807800_oyaf426-B9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012601215807800_oyaf426-B10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012601215807800_oyaf426-B11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026012601215807800_oyaf426-B12","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2024.42.16_suppl.4508","article-title":"Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN renal 101 phase 3 trial","volume":"42","author":"Motzer","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"2026012601215807800_oyaf426-B13","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026012601215807800_oyaf426-B14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026012601215807800_oyaf426-B15","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer","volume":"13","author":"Inomata","year":"2023","journal-title":"Sci Rep"},{"key":"2026012601215807800_oyaf426-B16","doi-asserted-by":"crossref","first-page":"e390290","DOI":"10.1200\/EDBK_390290","article-title":"Immune resistance mechanisms and the road to personalized immunotherapy","volume":"43","author":"Piper","year":"2023","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"2026012601215807800_oyaf426-B17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005780","article-title":"FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy","volume":"10","author":"Choueiri","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026012601215807800_oyaf426-B18","doi-asserted-by":"crossref","first-page":"104073","DOI":"10.1016\/j.esmoop.2024.104073","article-title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","volume":"9","author":"Choueiri","year":"2024","journal-title":"ESMO Open"},{"key":"2026012601215807800_oyaf426-B19","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.20.02295","article-title":"Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE)","volume":"38","author":"McKay","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026012601215807800_oyaf426-B20","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026012601215807800_oyaf426-B21","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort a)","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026012601215807800_oyaf426-B22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/1759-7714.15209","article-title":"Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Thorac Cancer"},{"key":"2026012601215807800_oyaf426-B23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/24684562251357795","article-title":"Role of immune check point inhibitor rechallenge in metastatic renal cell carcinoma","volume":"9","author":"B\u00f6lek","year":"2025","journal-title":"Kidney Cancer"},{"key":"2026012601215807800_oyaf426-B24","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1002\/onco.13812","article-title":"The impact of adverse events on health care resource utilization, costs, and mortality among patients treated with immune checkpoint inhibitors","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf426\/66133828\/oyaf426.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf426\/66133828\/oyaf426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf426\/66133828\/oyaf426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:22:03Z","timestamp":1769408523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf426\/8405397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf426","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"oyaf426"}}